The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review.

Health Sci Rep · 2025 · PMC12550263 · PMID 41141473

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Specifically, in the ADMIRAL trial, the CRc rate among patients with prior FLT3 inhibitor exposure was 52%, with a HR for OS of 0.60 (95% CI, 0.30–1.21), indicating a favorable trend toward improved survival.

also in 957 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.